|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400086564 |
|
最近更新日期: Date of Last Refreshed on: |
2024-07-05 10:17:27 |
|
注册时间: Date of Registration: |
2024-07-05 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
针刺干预癌因性疲乏气虚证的临床研究 |
|
Public title: |
Clinical study of acupuncture intervention for cancer related fatigue and deficiency of QI in TCM |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
针刺干预癌因性疲乏气虚证的临床研究 |
|
Scientific title: |
Clinical study of acupuncture intervention for cancer related fatigue and deficiency of QI in TCM |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨凡钰 |
研究负责人: |
黄海福 |
|
Applicant: |
Yang Fanyu |
Study leader: |
Huang Haifu |
|
申请注册联系人电话: Applicant telephone: |
+86 189 8848 9947 |
研究负责人电话: Study leader's telephone: |
+86 188 1393 9120 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zjlzyhyfy@126.com |
研究负责人电子邮件: Study leader's E-mail: |
huanghaifu2004@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
https://scrcam.gzucm.edu.cn/ |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
https://www.szftzy.com/ |
|
申请注册联系人通讯地址: |
广东省广州市番禺区大学城外环东路232号广州中医药大学 |
研究负责人通讯地址: |
广东省深圳市福田区北环大道6001号 |
|
Applicant address: |
Guangzhou University of Traditional Chinese Medicine, No.232, East Ring Road, Panyu District, Guangzhou, Guangdong Province |
Study leader's address: |
No.6001, Beihuan Avenue, Futian District, Shenzhen City, Guangdong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
广州中医药大学华南针灸研究中心 |
||
|
Applicant's institution: |
South China Research Center for Acupuncture and Moxibustion of Guangzhou University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
广州中医药大学深圳医院(福田) |
||
|
Affiliation of the Leader: |
Shenzhen Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine (Futian) |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
GZYLL(KY)-2024-028 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广州中医药大学深圳医院(福田)医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Shenzhen Hospital of Guangzhou University of Traditional Chinese Medicine (Futian) |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-06-20 00:00:00 |
||
|
伦理委员会联系人: |
卢琳 |
||
|
Contact Name of the ethic committee: |
Lu Lin |
||
|
伦理委员会联系地址: |
广东省深圳市福田区北环大道6001号 |
||
|
Contact Address of the ethic committee: |
No.6001, Beihuan Avenue, Futian District, Shenzhen City, Guangdong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 153 0298 5815 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
51749374@qq.com |
|
研究实施负责(组长)单位: |
广州中医药大学深圳医院(福田) |
||||||||||||||||||||||
|
Primary sponsor: |
Shenzhen Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine (Futian) |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省深圳市福田区北环大道6001号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.6001, Beihuan Avenue, Futian District, Shenzhen City, Guangdong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
广州中医药大学深圳医院(福田)肿瘤康复中心 |
||||||||||||||||||||||
|
Source(s) of funding: |
Guangzhou University of Shenzhen Hospital of Chinese Medicine (Futian) Cancer Rehabilitation Center |
||||||||||||||||||||||
|
Target disease: |
cancer related fatigue |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
采用单中心、随机对照试验设计,将针刺与假针刺进行对照研究,明确针对在给予维持治疗/姑息性治疗下的癌因性疲乏的患者中进行针刺干预与否的疗效差别。探讨维持治疗/姑息性治疗下,针刺治疗癌症患者疲乏症状的优化方案。 |
||||||||||||||||||||||
|
Objectives of Study: |
A single-center, randomized controlled trial design was acupuncture with sham acupuncture was used to clarify the efficacy of acupuncture intervention in patients with cancer fatigue given maintenance / palliative treatment. To explore the optimized scheme of acupuncture for fatigue symptoms in cancer patients under maintenance / palliative treatment. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
纳入病例进行同等的基础治疗,两组患者均为每日治疗一次,持续10天,共治疗10次。 试验组患者针刺关元、足三里、三阴交,辨证选穴加刺。施针医师双手常规消毒后对既定穴位揣穴定位,对针刺部位皮肤消毒后,垂直于皮肤快速入皮进针,过皮后缓慢刺入至相应深度(相应穴位人部),以包括适度提插捻转但不限于循法、刮法等手法促使针刺每穴得气。以施针医师针下沉紧为得气标准,不要求患者必须要有酸、麻、胀等针感,每次留针30分钟。 对照组患者根据对照及盲法原则使用假针刺:选取 11个固定的非经非穴的部位进行假针刺,施用一定的压力,不刺入皮肤,不诱发得气感,每次留针30分钟。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Cases included received equivalent basic treatment, and both groups were treated once daily for 10 days for a total of 10 treatments. Patients in the test group had acupuncture, Zusanli and triyin, and acupuncture by syndrome differentiation. After routine disinfection of the hands, the doctor located the established acupoints, disinfected the skin of the acupuncture site, quickly enters the needle perpendicular to the skin, and slowly pierced the skin to the corresponding depth (the corresponding acupoints), in order to include moderate lifting, twisting but not limited to law, scraping and other techniques to promote the acupuncture of each point. To apply the needle doctor needle sinking tight as the gas standard, do not require patients to have acid, numbness, distension and other needle feeling, keep the needle for 30 minutes each time. Patients in the control group used false acupuncture according to the principles of control and blind method: 11 fixed non-acupuncture parts were selected for false acupuncture, applied certain pressure, did not penetrate the skin, did not induce gas sensation, and the needle was left for 30 minutes each time. |
||||||||||||||||||||||
|
纳入标准: |
(1)确诊为恶性肿瘤者;(2)诊断为癌因性疲乏者;(3)预计生存期≥6个月;(4) Karnofsky(卡氏)体能状态评分(KPS)≥60分;(5)18岁≤年龄≤ 80岁;(6)病人知情同意,签署知情同意书,愿意接受本方案治疗;(7)治疗期间不计划接受手术、放疗治疗者。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) patients diagnosed with malignant tumor; (2) fatigue of cancer; (3) estimated survival period more than 6 months; (4) Karnofsky (Ka) physical status score (KPS≥60); (5) 18 ≤ages ≤80; (6) patients who signed informed consent and willingness to receive this protocol; (7) patients who are not scheduled to receive surgery or radiotherapy during treatment. |
||||||||||||||||||||||
|
排除标准: |
(1)处于妊娠或哺乳期妇女;(2)伴有严重的心、肝、肾、血液系统疾病或并发症者;(3)因精神异常不能合作者;(4)凝血功能障碍者,弥漫性血管内凝血或严重血小板减少伴有出血倾向,即血小板计数<35,000/μL;国际标准化比值(INR)>1.5;血红蛋白≤90g/dL;白细胞计数≤4×10^9/L;(5)针具恐惧症;(6)治疗过程中无法积极配合进行既定针刺治疗,依从性差者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) women in pregnancy or lactation; (2) patients with serious heart, liver, kidney, blood system diseases or complications; (3) inability to cooperate due to mental abnormalities; (4) diffuse vascular coagulation disorders or severe thrombocytopenia with bleeding tendency, namely platelet count <35,000 / μ L; international standardized ratio (INR)> 1.5; hemoglobin ≤90 g/dL; white blood cell count ≤4×10^9 / L; (5) needle phobia; (6) unable to actively cooperate with established needle therapy during treatment, poor compliance. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-07-08 00:00:00至 To 2025-01-03 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-07-08 00:00:00 至 To 2024-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用中央随机系统区组随机的随机数字产生方法分组,将纳入患者随机分配为针刺组和假针刺组。随机分配系统研发及执行由广州中医药大学临床研究与数据中心人员完成。分配隐藏机制及实施:当研究者确认合格病例之后,向中央随机系统提出申请,中央随机系统自动分配组别信息,并将组别信息发送给研究者,研究者根据患者组别信息向受试者分配干预措施。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Using the central randomization system, the included patients will be randomly assigned to the acupuncture group and the sham acupuncture group. The development and implementation of the randomization system was completed by the Clinical Research and Data Center of Guangzhou University of Chinese Medicine. Allocation concealment mechanism and implementation: After the investigator confirms the qualified case, apply to the central random system, which will automatically assign the group information and send the group information to the investigator, and the investigator assigns the intervention to the subjects according to the patient group information. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
对受试者、主要研究者实施盲法。负责进行疗效评价的人员为第三方人员,不会知晓患者的分组情况。对数据统计的数据库设立一级盲底,统计师不知晓具体的组别情况。所有操作过程按照既定标准操作规程完成。 |
|
Blinding: |
Blinding of the subject and the principal investigator.The person responsible for the efficacy evaluation is a third party and will not know the grouping of patients.Set up a level 1 blind information for the database of data statistics, and the statisticians do not know the specific group situation.All operating procedures are completed according to the established SOP. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2025年1月31日于广州中医药大学深圳医院(福田)内公开 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
It will be released in Shenzhen Hospital of Guangzhou University of Traditional Chinese Medicine (Futian) on January 31,2025 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |